Can AbCellera Biologics (ABCL)’s Vertex Pharmaceuticals Incorporated (VRTX) Deal Turn its TCE Platform Into a Breakthrough?

insidermonkey.com · 2026-08-14

On July 29, AbCellera Biologics Inc.

TickrTrends take: Vertex Pharmaceuticals operates in the Healthcare sector where the company is currently assessed as fairly valued by TickrTrends. A valuation-focused reader should monitor how the AbCellera partnership develops, as successful applications of the TCE platform could either validate the current valuation or create upside potential depending on the commercial outcomes of collaborative programs. The therapeutic value and market adoption of any resulting assets from this deal will be key to determining whether Vertex's current valuation appropriately reflects the opportunity.

Read the full story at insidermonkey.com →